FDA approves Yutrepia, inhaled treprostinil, for PAH and PH-ILD
The FDA has approved Yutrepia, an inhaled treprostinil formulation, for the treatment of PAH and PH-ILD, two forms of pulmonary hypertension.| Pulmonary Hypertension News
The FDA has approved Yutrepia, an inhaled treprostinil formulation, for the treatment of PAH and PH-ILD, two forms of pulmonary hypertension.| Pulmonary Hypertension News
Read about the various types of pulmonary hypertension, and their causes, as classified by the World Health Organization (WHO).| Pulmonary Hypertension News
Category archive page for News.| Pulmonary Hypertension News
Lindsey Shapiro is a science writer for Pulmonary Hypertension News with a PhD in neuroscience. She covers the latest news and information on a variety of pulmonary hypertension topics.| Pulmonary Hypertension News
Pulmonary hypertension (PH) is a chronic and progressive disease associated with high blood pressure in the blood vessels that supply the lungs, known as the pulmonary arteries. Read more about PH here.| Pulmonary Hypertension News
